<DOC>
	<DOCNO>NCT00275132</DOCNO>
	<brief_summary>RATIONALE : Erlotinib may stop growth tumor cell block enzymes need cell growth . It yet know whether erlotinib effective placebo treat non-small cell lung cancer . PURPOSE : This randomized phase III trial study erlotinib see well work compare placebo treat patient stage III stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Erlotinib Treating Patients With Stage III Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare survival patient stage IIIB IV non-small cell lung cancer suitable first-line chemotherapy treat erlotinib v placebo . Secondary - Compare progression-free survival response rate . - Compare toxicity . - Compare quality life . - Compare cost-effectiveness . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral erlotinib daily 24 month . - Arm II : Patients receive oral placebo daily 24 month . Quality life assess periodically . After completion study treatment , patient follow periodically survival . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 664 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer Advanced disease ( stage IIIB IV ) Diagnosis within 62 day prior randomization Not suitable firstline chemotherapy , define follow criteria* : ECOG performance status 23 ECOG performance status 01 AND creatinine clearance &lt; 60 mL/min NOTE : *These criterion imply patient unsuitable chemotherapy ; patient consider unsuitable case case basis No symptomatic brain metastasis PATIENT CHARACTERISTICS : Estimated life expectancy least 8 week Able take oral medication Not pregnant nursing Fertile patient must use effective contraception No severe uncontrolled infection No unstable angina No myocardial infarction within past month No uncontrolled inflammatory bowel disease ( e.g. , Crohn 's disease ulcerative colitis ) No acute renal failure Bilirubin &lt; 2 time upper limit normal ( ULN ) Transaminases &lt; 2 time ULN ( 5 time ULN liver metastasis present ) Creatinine &lt; 5 time ULN No evidence significant laboratory find uncontrolled medical illness would interfere study treatment result comparison render patient high risk treatment complication No prior current malignant disease likely interfere study treatment comparison PRIOR CONCURRENT THERAPY : No prior chemotherapy No prior biological anticancer therapy ( e.g. , gefitinib , thalidomide , cetuximab ) No prior palliative radiotherapy Prior palliative radiotherapy bone metastases allow within past 2 week No concurrent cyclooxygenase2 inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>